

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

ANNOUNCEMENT

POLL RESULTS OF THE 2020 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 22 JANUARY 2020

References are made to the notice of 2019 4th EGM dated 13 November 2019, revised notice of 2019 4th EGM dated 16 December 2019, the supplemental notice to the revised notice of 2019 4th EGM dated 3 January 2020 and the circular dated 6 January 2020 (the “**Circular**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE 2020 1ST EGM

The 2020 1st EGM was convened at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC on Wednesday, 22 January 2020. The 2020 1st EGM was convened legally and effectively in accordance with the Company Law of the PRC and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Association.

As at the date of the 2020 1st EGM, the total number of issued shares of the Company (the “**Shares**”) was 448,820,050 Shares (of which 226,200,000 were Domestic Shares and 222,620,050 were H Shares), all of which entitled the holders to attend the 2020 1st EGM and vote for or against or abstain from voting on the resolutions proposed at the 2020 1st EGM.

Shareholders, either in person or by proxy, holding an aggregate of 97,282,979 Shares with voting rights, representing approximately 21.68% of the total number of the issued Shares with voting rights, attended the 2020 1st EGM.

Guangdong HEC Technology Holding Co., Ltd. (廣東東陽光科技控股股份有限公司) (the “**Parent Company**”), which held approximately 50.52% of the equity interests in the Company as at the date of the 2020 1st EGM, was required to abstain from voting on all the resolutions (the “**Resolutions**”) in relation to the proposed discloseable transaction and connected transaction under the Sale and Purchase Agreement and Supplemental Agreement entered into between the Company and Sunshine Lake Pharma as the Parent Company had material interest in the Sale and Purchase Agreement and Supplemental Agreement. Save as disclosed herein, no other Shareholder was required to abstain from voting on any of the resolutions proposed at the 2020 1st EGM under the Listing Rules. Accordingly, there were 222,082,650 shares of the Company, representing approximately 49.48% of the total number of the issued shares of the Company, entitling the Shareholders to attend and vote on the Resolutions at the 2020 1st EGM. There was no Share entitling the holder to attend the 2020 1st EGM and abstain from voting in favour of any of the proposed resolutions under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions. All the proposed resolutions were voted by way of poll. Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for vote-taking at the 2020 1st EGM. One representative from the Shareholders and one supervisor of the Company also acted as the scrutineers for the vote-taking and vote-tabulation.

Poll Results of the 2020 1st EGM

The poll results of the 2020 1st EGM are as follows:

SPECIAL RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed transaction under the Sale and Purchase Agreement dated 13 November 2019 entered into between the Company and Sunshine Lake Pharma.	77,758,086 (79.929795%)	11,247,790 (11.561930%)	8,277,103 (8.508275%)
2.	To consider and approve the proposed transaction under the Supplemental Agreement dated 26 December 2019 entered into between the Company and Sunshine Lake Pharma.	78,013,686 (83.102396%)	7,585,790 (8.080599%)	8,277,103 (8.817005%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the 2020 1st EGM were cast in favour of the resolutions numbered 1 and 2, these resolutions were duly passed as special resolutions.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
22 January 2020

As of the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yanguai and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. FU Hailiang and Mr. ZHAO Dayao as independent non-executive Directors.